Cargando…

A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial

BACKGROUND: Intensive lifestyle interventions are effective in reducing the risk of type 2 diabetes, but the implementation of learnings from landmark studies is expensive and time consuming. The availability of digital lifestyle interventions is increasing, but evidence of their effectiveness is li...

Descripción completa

Detalles Bibliográficos
Autores principales: Staite, Emily, Bayley, Adam, Al-Ozairi, Ebaa, Stewart, Kurtis, Hopkins, David, Rundle, Jennifer, Basudev, Neel, Mohamedali, Zahra, Ismail, Khalida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391669/
https://www.ncbi.nlm.nih.gov/pubmed/32459651
http://dx.doi.org/10.2196/15448
_version_ 1783564694671327232
author Staite, Emily
Bayley, Adam
Al-Ozairi, Ebaa
Stewart, Kurtis
Hopkins, David
Rundle, Jennifer
Basudev, Neel
Mohamedali, Zahra
Ismail, Khalida
author_facet Staite, Emily
Bayley, Adam
Al-Ozairi, Ebaa
Stewart, Kurtis
Hopkins, David
Rundle, Jennifer
Basudev, Neel
Mohamedali, Zahra
Ismail, Khalida
author_sort Staite, Emily
collection PubMed
description BACKGROUND: Intensive lifestyle interventions are effective in reducing the risk of type 2 diabetes, but the implementation of learnings from landmark studies is expensive and time consuming. The availability of digital lifestyle interventions is increasing, but evidence of their effectiveness is limited. OBJECTIVE: This randomized controlled trial (RCT) aimed to test the feasibility of a web-based diabetes prevention program (DPP) with step-dependent feedback messages versus a standard web-based DPP in people with prediabetes. METHODS: We employed a two-arm, parallel, single-blind RCT for people at high risk of developing diabetes. Patients with a hemoglobin A(1c) (HbA(1c)) level of 39-47 mmol/mol were recruited from 21 general practices in London. The intervention integrated a smartphone app delivering a web-based DPP course with SMS texts incorporating motivational interviewing techniques and step-dependent feedback messages delivered via a wearable device over 12 months. The control group received the wearable technology and access to the web-based DDP but not the SMS texts. As this was a feasibility study, the primary aim was to estimate potential sample size at different stages of the study, including the size of the target study population and the proportion of participants who consented, were randomized, and completed follow-up. We also measured the main outcomes for a full-scale RCT, namely, change in weight and physical activity at 6- and 12-month follow-ups, and secondary outcomes, including changes in the HbA(1c) level, blood pressure, waist circumference, waist-to-hip ratio, and lipid levels. RESULTS: We enrolled 200 participants: 98 were randomized to the intervention and 102 were randomized to the control group. The follow-up rate was higher in the control group (87/102, 85.3%) than in the intervention group (69/98, 70%) at 12 months. There was no treatment effect on weight at 6 months (mean difference 0.15; 95% CI −0.93 to 1.23) or 12 months (mean difference 0.07 kg; 95% CI −1.29 to 1.44) or for physical activity levels at 6 months (mean difference −382.90 steps; 95% CI −860.65 to 94.85) or 12 months (mean difference 92.64 steps; 95% CI −380.92 to 566.20). We did not observe a treatment effect on the secondary outcomes measured at the 6-month or 12-month follow-up. For the intervention group, the mean weight was 92.33 (SD 15.67) kg at baseline, 91.34 (SD 16.04) kg at 6 months, and 89.41 (SD 14.93) kg at 12 months. For the control group, the mean weight was 92.59 (SD 17.43) kg at baseline, 91.71 (SD 16.48) kg at 6 months, and 91.10 (SD 15.82) kg at 12 months. In the intervention group, the mean physical activity was 7308.40 (SD 4911.93) steps at baseline, 5008.76 (SD 2733.22) steps at 6 months, and 4814.66 (SD 3419.65) steps at 12 months. In the control group, the mean physical activity was 7599.28 (SD 3881.04) steps at baseline, 6148.83 (SD 3433.77) steps at 6 months, and 5006.30 (SD 3681.1) steps at 12 months. CONCLUSIONS: This study demonstrates that it is feasible to successfully recruit and retain patients in an RCT of a web-based DPP. TRIAL REGISTRATION: ClinicalTrials.gov NCT02919397; http://clinicaltrials.gov/ct2/show/NCT02919397
format Online
Article
Text
id pubmed-7391669
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-73916692020-08-12 A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial Staite, Emily Bayley, Adam Al-Ozairi, Ebaa Stewart, Kurtis Hopkins, David Rundle, Jennifer Basudev, Neel Mohamedali, Zahra Ismail, Khalida JMIR Mhealth Uhealth Original Paper BACKGROUND: Intensive lifestyle interventions are effective in reducing the risk of type 2 diabetes, but the implementation of learnings from landmark studies is expensive and time consuming. The availability of digital lifestyle interventions is increasing, but evidence of their effectiveness is limited. OBJECTIVE: This randomized controlled trial (RCT) aimed to test the feasibility of a web-based diabetes prevention program (DPP) with step-dependent feedback messages versus a standard web-based DPP in people with prediabetes. METHODS: We employed a two-arm, parallel, single-blind RCT for people at high risk of developing diabetes. Patients with a hemoglobin A(1c) (HbA(1c)) level of 39-47 mmol/mol were recruited from 21 general practices in London. The intervention integrated a smartphone app delivering a web-based DPP course with SMS texts incorporating motivational interviewing techniques and step-dependent feedback messages delivered via a wearable device over 12 months. The control group received the wearable technology and access to the web-based DDP but not the SMS texts. As this was a feasibility study, the primary aim was to estimate potential sample size at different stages of the study, including the size of the target study population and the proportion of participants who consented, were randomized, and completed follow-up. We also measured the main outcomes for a full-scale RCT, namely, change in weight and physical activity at 6- and 12-month follow-ups, and secondary outcomes, including changes in the HbA(1c) level, blood pressure, waist circumference, waist-to-hip ratio, and lipid levels. RESULTS: We enrolled 200 participants: 98 were randomized to the intervention and 102 were randomized to the control group. The follow-up rate was higher in the control group (87/102, 85.3%) than in the intervention group (69/98, 70%) at 12 months. There was no treatment effect on weight at 6 months (mean difference 0.15; 95% CI −0.93 to 1.23) or 12 months (mean difference 0.07 kg; 95% CI −1.29 to 1.44) or for physical activity levels at 6 months (mean difference −382.90 steps; 95% CI −860.65 to 94.85) or 12 months (mean difference 92.64 steps; 95% CI −380.92 to 566.20). We did not observe a treatment effect on the secondary outcomes measured at the 6-month or 12-month follow-up. For the intervention group, the mean weight was 92.33 (SD 15.67) kg at baseline, 91.34 (SD 16.04) kg at 6 months, and 89.41 (SD 14.93) kg at 12 months. For the control group, the mean weight was 92.59 (SD 17.43) kg at baseline, 91.71 (SD 16.48) kg at 6 months, and 91.10 (SD 15.82) kg at 12 months. In the intervention group, the mean physical activity was 7308.40 (SD 4911.93) steps at baseline, 5008.76 (SD 2733.22) steps at 6 months, and 4814.66 (SD 3419.65) steps at 12 months. In the control group, the mean physical activity was 7599.28 (SD 3881.04) steps at baseline, 6148.83 (SD 3433.77) steps at 6 months, and 5006.30 (SD 3681.1) steps at 12 months. CONCLUSIONS: This study demonstrates that it is feasible to successfully recruit and retain patients in an RCT of a web-based DPP. TRIAL REGISTRATION: ClinicalTrials.gov NCT02919397; http://clinicaltrials.gov/ct2/show/NCT02919397 JMIR Publications 2020-07-15 /pmc/articles/PMC7391669/ /pubmed/32459651 http://dx.doi.org/10.2196/15448 Text en ©Emily Staite, Adam Bayley, Ebaa Al-Ozairi, Kurtis Stewart, David Hopkins, Jennifer Rundle, Neel Basudev, Zahra Mohamedali, Khalida Ismail. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 15.07.2020. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mHealth and uHealth, is properly cited. The complete bibliographic information, a link to the original publication on http://mhealth.jmir.org/, as well as this copyright and license information must be included.
spellingShingle Original Paper
Staite, Emily
Bayley, Adam
Al-Ozairi, Ebaa
Stewart, Kurtis
Hopkins, David
Rundle, Jennifer
Basudev, Neel
Mohamedali, Zahra
Ismail, Khalida
A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title_full A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title_fullStr A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title_full_unstemmed A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title_short A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title_sort wearable technology delivering a web-based diabetes prevention program to people at high risk of type 2 diabetes: randomized controlled trial
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391669/
https://www.ncbi.nlm.nih.gov/pubmed/32459651
http://dx.doi.org/10.2196/15448
work_keys_str_mv AT staiteemily awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT bayleyadam awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT alozairiebaa awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT stewartkurtis awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT hopkinsdavid awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT rundlejennifer awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT basudevneel awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT mohamedalizahra awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT ismailkhalida awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT staiteemily wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT bayleyadam wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT alozairiebaa wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT stewartkurtis wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT hopkinsdavid wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT rundlejennifer wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT basudevneel wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT mohamedalizahra wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT ismailkhalida wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial